Asthma Therapeutics Market to 2020 – Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

The global prevalence of asthma, a chronic inflammatory disease of the airways, has risen considerably in recent decades and is expected to reach 400 million people by 2025. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity.

Get Sample Copy of Report with TOC@

The marketed products landscape comprises a wide range of therapies classified either as long-term maintenance therapy aimed at controlling persistent asthma, or quick-relief medication for exacerbations and acute symptoms. However, despite the range of treatment options available, significant unmet need remains for safer therapies with improved dosing regimens, and, among the severe, inadequately controlled patient population, for therapies that can improve asthma control.


Inhaled Corticosteroids (ICS), with or without a Long-Acting Beta Agonist (LABA), will remain the mainstay of asthma maintenance therapy.

Will current ICS/LABA blockbusters such as Advair and Symbicort maintain their prominent roles in the treatment algorithm?

Treatment options will improve most significantly for patients with severe, inadequately controlled asthma.

How do pipeline therapies indicated for the severe patient population differ from currently marketed treatment options?

Which unmet needs will these therapies address in the severe patient population?

The pipeline shows evidence of significant diversification and innovation above current market trends.

Biologics are gaining prominence. While the current market is almost exclusively dominated by small molecules, biologics currently account for approximately one third of pipeline molecules.

Will the pipeline biologics achieve strong market infiltration?

How will Xolair, the only currently marketed biologic, be impacted by the anticipated approvals of pipeline biologics?

Whereas molecular targets such as glucocorticoid receptors and adrenergic receptors dominate the marketed products landscape, immune/inflammatory system targets comprise the largest target family group in the pipeline. In addition, many components of the inflammatory response are targeted that are not currently represented in the market.

Which immune/inflammatory system targets demonstrate most promise?

How will this translate into improved treatment options for patients?

How have these pipeline trends impacted the clinical trials landscape?

How do different molecule types and molecular targets compare in terms of average failure rate, clinical trial duration, and clinical trial size?

Which molecule types and molecular targets require greater levels of investment and which are associated with higher levels of risk?

Despite generic sales erosion resulting from patent expirations, rising asthma prevalence and new product approvals will lead to marginal market growth over the forecast period.

Which patent expirations will have the most significant impact on the market?

How will different treatment usage patterns impact growth in the eight major markets?

Reasons To Buy

This report will enable you to:

Understand the clinical context of the asthma indication, and the global burden of the disease, by considering epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment options.

Recognize the products and companies that dominate the current commercial landscape and understand how opportunities and threats over the coming years will modify this landscape.

Identify key pipeline trends in molecule types and molecular targets and appreciate how such trends will influence the future treatment of asthma.

Ascertain the late-stage pipeline molecules that have demonstrated the most promise in asthma based on clinical trial data.

Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by phase of development, molecule type, and molecular target.

Discern variances in treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain and Japan.

Discover how strategic consolidations have shaped the current asthma pipeline and marketed product landscapes.

Make an enquiry @

About Us

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.

Contact Us:

Joel John

Deerfield Beach, Florida 33442

United States

Toll Free: +1-855-465-4651 (USA-CANADA)

Tel: +1-386-310-3803

About Zedong Alton

Alton Zedong is an experienced Market Research, Customer Insights & Consulting professional, covering latest industry and market updates on Electronics, Semiconductor and ICT domain.

View all posts by Zedong Alton →

Leave a Reply

Your email address will not be published. Required fields are marked *